PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Clinical Pharmacy, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.\', \'Center for Joint Research Facilities Support, Research Promotion and Support Headquarters, Fujita Health University, Toyoake, Aichi, Japan.\', \'Department of Biomedical Molecular Sciences, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.\', \'Departments of Microbiology and Infectious Diseases, Fujita Health University School of Medicine, Toyoake, Aichi, Japan; Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. Electronic address: yoheidoi@fujita-hu.ac.jp.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S1201-9712(21)01219-410.1016/j.ijid.2021.12.324
?:hasPublicationType
?:journal
  • International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
is ?:pmid of
?:pmid
?:pmid
  • 34910957
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Baseline uric acid levels and steady-state favipiravir concentrations are associated with occurrence of hyperuricemia among COVID-19 patients.
?:type
?:year
  • 2022

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34910957>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34910957>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all